Prostate cancer
Sequencing treatments in mCRPC patients without HRR gene mutations

Case 3: Rui

Rui, 69 years old, has a history of PCa.

Medical history:

  • Diagnosed with high-volume mHSPC 1 year ago
    • PSA: 63 ng/ml
    • Bone and CT scan: multiple bone metastases
    • Treatment with ADT + docetaxel + darolutamide was started
    • After 6 cycles of docetaxel, his PSA dropped to 2 ng/ml
  • Current situation, 6 months after stopping docetaxel, treatment with darolutamide is still ongoing:
    • No comorbidities
    • No relevant family history
    • ECOG PS: 0
    • Asymptomatic
    • Rising PSA: 13 ng/ml
    • Testosterone: 17 ng/dl (0.6 nmol/L)
    • Bone and CT scan: 3 new bone metastases, not present on scans 6 months ago, few enlarged pelvic lymph nodes (all <3 cm)
    • PSMA-PET/CT: concordant with bone and CT scan, all lesions PSMA positive and higher PSMA expression than liver
    • No actionable germline or somatic mutations detected

Which of the following treatment options would you choose for this patient?